VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | Structural variants in multiple myeloma: impact on outcomes & potential drug targets

Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone, New York, NY, discusses the occurrence of structural variants in multiple myeloma, commenting on the impact of chromoplexy and chromothripsis on patient outcomes, and highlighting the possibility of finding new drivers that can be used as targets for therapy. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter